April 7, 2022

Labcorp initiates quarterly dividend

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 7, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock. 
Read more »
April 5, 2022

New Immundiagnostik test simplifies detecting, measuring unintentional gluten consumption

MANCHESTER, N.H., April 5, 2022 — Immundiagnostik, Inc., the North American subsidiary of Immundiagnostik AG, has collaborated with Labcorp (NYSE: LH), a leading global life sciences company, to help individuals detect and quantify unintentional gluten consumption by utilizing a new fecal gluten test. The quantitative test developed by Immundiagnostik and offered exclusively through Labcorp detects the presence of gluten in a patient’s stool sample and has a high sensitivity and specificity.
Read more »

New Immundiagnostik Test Simplifies Detecting, Measuring Unintentional Gluten Consumption

Labcorp Renews Strategic Partnership with Medidata to Provide Suite of Clinical Trial Technologies and Services

New Labcorp Offering Makes Detecting, Measuring Unintentional Gluten Consumption Simple and Effective

Woman putting mask on child to protect from COVID-19

COVID-19 Antibody levels: More may be better

Since the beginning of the COVID-19 pandemic, there’s been a lot of talk about testing. Usually, people are referring to diagnostic testing performed with a nasal swab. However, another type of testing—one that requires a blood test and that you may not know about—has been around nearly the whole time.

That testing is for assessing antibody levels against SARS-CoV-2, the virus that causes COVID-19.